Humoral immunoresponse elicited against an adenoviral-based SARS-CoV-2 coronavirus vaccine in elderly patients

The early sequencing of the SARS-CoV-2 viral genome allowed for a speedy development of effective vaccines against the virus. Nevertheless, age-related immunosenescence, the inability to mount strong immune responses, still represents a major obstacle. Here, in a group of 149 elderly volunteers (70–...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomas-Grau, Rodrigo Hernán, Maldonado-Galdeano, Carolina, López, Mónica Aguilar, Pingitore, Esteban Vera, Aznar, Patricia, Alcorta, María Elena, del Mar Vélez, Eva María, Stagnetto, Agustín, Soliz-Santander, Silvana Estefanía, Ávila, César Luís, Socias, Sergio Benjamín, Costas, Dardo, Chahla, Rossana Elena, Perdigón, Gabriela, Chehín, Rosana Nieves, Ploper, Diego, Cazorla, Silvia Inés
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550251/
https://www.ncbi.nlm.nih.gov/pubmed/36152043
http://dx.doi.org/10.18632/aging.204299
_version_ 1784805839666675712
author Tomas-Grau, Rodrigo Hernán
Maldonado-Galdeano, Carolina
López, Mónica Aguilar
Pingitore, Esteban Vera
Aznar, Patricia
Alcorta, María Elena
del Mar Vélez, Eva María
Stagnetto, Agustín
Soliz-Santander, Silvana Estefanía
Ávila, César Luís
Socias, Sergio Benjamín
Costas, Dardo
Chahla, Rossana Elena
Perdigón, Gabriela
Chehín, Rosana Nieves
Ploper, Diego
Cazorla, Silvia Inés
author_facet Tomas-Grau, Rodrigo Hernán
Maldonado-Galdeano, Carolina
López, Mónica Aguilar
Pingitore, Esteban Vera
Aznar, Patricia
Alcorta, María Elena
del Mar Vélez, Eva María
Stagnetto, Agustín
Soliz-Santander, Silvana Estefanía
Ávila, César Luís
Socias, Sergio Benjamín
Costas, Dardo
Chahla, Rossana Elena
Perdigón, Gabriela
Chehín, Rosana Nieves
Ploper, Diego
Cazorla, Silvia Inés
author_sort Tomas-Grau, Rodrigo Hernán
collection PubMed
description The early sequencing of the SARS-CoV-2 viral genome allowed for a speedy development of effective vaccines against the virus. Nevertheless, age-related immunosenescence, the inability to mount strong immune responses, still represents a major obstacle. Here, in a group of 149 elderly volunteers (70–96 years old), evolution of the humoral immune response over time to Gam-COVID-Vac (Sputnik V), a vaccine based on heterologous recombinant adenovirus-26 (Ad26) and adenovirus-5 (Ad5) carrying the Spike genome, was analyzed by an anti-RBD ELISA. At 28 days post vaccination (dpv), a seroconversion rate of 91% was achieved, showing the importance of administering at least two doses of Gam-COVID-Vac to elicit a robust immune response, especially in elderly individuals without previous SARS-CoV-2 infection. Interestingly, IgG specific antibodies that reached their highest titers around 28 dpv (median = 740), persisted without significant decrease after 60 dpv (median = 650). After 90 dpv, IgG titers began to drop, and at 180 dpv only 44.7% of the elderly individuals remained with detectable anti-RBD IgG antibodies. No significant differences were observed in specific humoral immune responses between genders at early times point. However, at 60 dpv anti-RBD titers were more persistent in elderly females, and only dropped at 90 dpv (p < 0.0001). As expected, the highest antibodies titers were elicited in the youngest subgroup (70–74 years). Our results show that Gam-COVID-Vac was able to deal with the ageing of the immune system, eliciting a robust immune response in an elderly cohort, which lasted approximately 90 dpv at high levels, and protected against COVID-19.
format Online
Article
Text
id pubmed-9550251
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Impact Journals
record_format MEDLINE/PubMed
spelling pubmed-95502512022-10-11 Humoral immunoresponse elicited against an adenoviral-based SARS-CoV-2 coronavirus vaccine in elderly patients Tomas-Grau, Rodrigo Hernán Maldonado-Galdeano, Carolina López, Mónica Aguilar Pingitore, Esteban Vera Aznar, Patricia Alcorta, María Elena del Mar Vélez, Eva María Stagnetto, Agustín Soliz-Santander, Silvana Estefanía Ávila, César Luís Socias, Sergio Benjamín Costas, Dardo Chahla, Rossana Elena Perdigón, Gabriela Chehín, Rosana Nieves Ploper, Diego Cazorla, Silvia Inés Aging (Albany NY) Research Paper The early sequencing of the SARS-CoV-2 viral genome allowed for a speedy development of effective vaccines against the virus. Nevertheless, age-related immunosenescence, the inability to mount strong immune responses, still represents a major obstacle. Here, in a group of 149 elderly volunteers (70–96 years old), evolution of the humoral immune response over time to Gam-COVID-Vac (Sputnik V), a vaccine based on heterologous recombinant adenovirus-26 (Ad26) and adenovirus-5 (Ad5) carrying the Spike genome, was analyzed by an anti-RBD ELISA. At 28 days post vaccination (dpv), a seroconversion rate of 91% was achieved, showing the importance of administering at least two doses of Gam-COVID-Vac to elicit a robust immune response, especially in elderly individuals without previous SARS-CoV-2 infection. Interestingly, IgG specific antibodies that reached their highest titers around 28 dpv (median = 740), persisted without significant decrease after 60 dpv (median = 650). After 90 dpv, IgG titers began to drop, and at 180 dpv only 44.7% of the elderly individuals remained with detectable anti-RBD IgG antibodies. No significant differences were observed in specific humoral immune responses between genders at early times point. However, at 60 dpv anti-RBD titers were more persistent in elderly females, and only dropped at 90 dpv (p < 0.0001). As expected, the highest antibodies titers were elicited in the youngest subgroup (70–74 years). Our results show that Gam-COVID-Vac was able to deal with the ageing of the immune system, eliciting a robust immune response in an elderly cohort, which lasted approximately 90 dpv at high levels, and protected against COVID-19. Impact Journals 2022-09-21 /pmc/articles/PMC9550251/ /pubmed/36152043 http://dx.doi.org/10.18632/aging.204299 Text en Copyright: © 2022 Tomas-Grau et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Tomas-Grau, Rodrigo Hernán
Maldonado-Galdeano, Carolina
López, Mónica Aguilar
Pingitore, Esteban Vera
Aznar, Patricia
Alcorta, María Elena
del Mar Vélez, Eva María
Stagnetto, Agustín
Soliz-Santander, Silvana Estefanía
Ávila, César Luís
Socias, Sergio Benjamín
Costas, Dardo
Chahla, Rossana Elena
Perdigón, Gabriela
Chehín, Rosana Nieves
Ploper, Diego
Cazorla, Silvia Inés
Humoral immunoresponse elicited against an adenoviral-based SARS-CoV-2 coronavirus vaccine in elderly patients
title Humoral immunoresponse elicited against an adenoviral-based SARS-CoV-2 coronavirus vaccine in elderly patients
title_full Humoral immunoresponse elicited against an adenoviral-based SARS-CoV-2 coronavirus vaccine in elderly patients
title_fullStr Humoral immunoresponse elicited against an adenoviral-based SARS-CoV-2 coronavirus vaccine in elderly patients
title_full_unstemmed Humoral immunoresponse elicited against an adenoviral-based SARS-CoV-2 coronavirus vaccine in elderly patients
title_short Humoral immunoresponse elicited against an adenoviral-based SARS-CoV-2 coronavirus vaccine in elderly patients
title_sort humoral immunoresponse elicited against an adenoviral-based sars-cov-2 coronavirus vaccine in elderly patients
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550251/
https://www.ncbi.nlm.nih.gov/pubmed/36152043
http://dx.doi.org/10.18632/aging.204299
work_keys_str_mv AT tomasgraurodrigohernan humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients
AT maldonadogaldeanocarolina humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients
AT lopezmonicaaguilar humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients
AT pingitoreestebanvera humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients
AT aznarpatricia humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients
AT alcortamariaelena humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients
AT delmarvelezevamaria humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients
AT stagnettoagustin humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients
AT solizsantandersilvanaestefania humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients
AT avilacesarluis humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients
AT sociassergiobenjamin humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients
AT costasdardo humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients
AT chahlarossanaelena humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients
AT perdigongabriela humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients
AT chehinrosananieves humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients
AT ploperdiego humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients
AT cazorlasilviaines humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients